VBI Vaccines Gets a Buy Rating from Noble Financial

By Austin Angelo

Noble Financial analyst Kumaraguru Raja reiterated a Buy rating on VBI Vaccines (NASDAQ: VBIV) on July 27. The company’s shares closed on Friday at $4.64.

According to TipRanks.com, Raja is a 1-star analyst with an average return of -11.1% and a 50.0% success rate. Raja covers the Healthcare sector, focusing on stocks such as ContraVir Pharmaceuticals Inc, Adamas Pharmaceuticals, and Corbus Pharmaceuticals.

VBI Vaccines has an analyst consensus of Moderate Buy.

Based on VBI Vaccines’ latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $127K and GAAP net loss of $8.64 million. In comparison, last year the company earned revenue of $104K and had a GAAP net loss of $6.89 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

VBI Vaccines, Inc. is a biopharmaceutical company, which develops next generation vaccines to address unmet needs in infectious disease and immuno-oncology. Its products portfolio includes Sci-B-Vac, HBV, CMV Vaccine, GBM Immunotherapy and RSV Vaccine. The company is headquartered in Cambridge, MA.